View More Recent Stories

Jan 28, 2019 07:00AM First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
Dec 20, 2018 05:41PM Ionis Announces Plans for Management Transitions in 2020
Dec 6, 2018 07:33AM Biogen (BIIB) Exercises Option with Ionis (IONS) to Develop, Commercialize Investigational Treatment BIIB067 for Subtype of Familial ALS Based on Positive Phase 1 Data
Dec 6, 2018 07:30AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
Nov 27, 2018 07:00AM First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting
Nov 13, 2018 07:07AM Ionis Pharmaceuticals to Present at Jefferies 2018 London Healthcare Conference
Nov 12, 2018 06:58AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Highlight Phase 2 Results on AKCEA-APO(a)-LRx in Late-Breaking Clinical Trial Presentation
Nov 12, 2018 06:55AM Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
Nov 12, 2018 06:55AM Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
Nov 9, 2018 07:07AM Ionis Pharmaceuticals to Host Investor Day
Nov 8, 2018 07:37AM Akcea Therapeutics (AKCA), Ionis (IONS) Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at AHA
Nov 8, 2018 07:00AM Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
Nov 8, 2018 07:00AM Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
Nov 7, 2018 07:00AM Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 6, 2018 07:00AM Ionis Reports Third Quarter 2018 Financial Results
Oct 31, 2018 07:00AM Advances in Ionis' Novel Antisense Technology to be Presented at 2018 Society for Neuroscience Meeting
Oct 24, 2018 07:00AM Ionis Pharmaceuticals to Hold Third Quarter 2018 Financial Results Webcast
Oct 23, 2018 07:00AM Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in Science
Oct 22, 2018 08:47AM Ionis Pharmaceuticals (IONS) Reports New Phase 1b/2 Trial Data on Danvatirsen (formerly IONIS-STAT3-2.5Rx, aka AZD9150) at ESMO 2018
Oct 22, 2018 08:45AM Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology
Oct 10, 2018 09:09AM Ionis Pharmaceuticals (IONS) Enters Pact with Roche to Develop IONIS-FB-L Rx for Complement-Mediated
Oct 10, 2018 09:07AM Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases
Oct 8, 2018 06:16AM Akcea (AKCA), Ionis (IONS) Receive FDA Approval of TEGSEDI (Earlier)
Oct 5, 2018 05:32PM Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Oct 5, 2018 05:32PM Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Oct 4, 2018 04:05PM Akcea Therapeutics (AKCA) Announce Approval of TEGSEDI in Canada
Oct 4, 2018 04:05PM Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada
Oct 4, 2018 04:05PM Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada
Oct 4, 2018 04:05PM Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada
Apr 20, 2018 06:30AM Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
Feb 14, 2018 05:01PM The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
Sep 7, 2017 10:00AM Akcea Therapeutics, Inc. (Nasdaq: AKCA) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories